229 related articles for article (PubMed ID: 25973894)
1. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
Connor JR; Zhang X; Nixon AM; Webb B; Perno JR
PLoS One; 2015; 10(5):e0125272. PubMed ID: 25973894
[TBL] [Abstract][Full Text] [Related]
2. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
3. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
Hempel JC; Poppelaars F; Gaya da Costa M; Franssen CF; de Vlaam TP; Daha MR; Berger SP; Seelen MA; Gaillard CA
Am J Nephrol; 2017; 45(1):49-59. PubMed ID: 27889746
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
5. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.
Johnson AC; Becker K; Zager RA
Am J Physiol Renal Physiol; 2010 Aug; 299(2):F426-35. PubMed ID: 20504881
[TBL] [Abstract][Full Text] [Related]
6. Oxidative effect of several intravenous iron complexes in the rat.
Bailie GR; Schuler C; Leggett RE; Li H; Li HD; Patadia H; Levin R
Biometals; 2013 Jun; 26(3):473-8. PubMed ID: 23681275
[TBL] [Abstract][Full Text] [Related]
7. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
8. Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
Praschberger M; Haider K; Cornelius C; Schitegg M; Sturm B; Goldenberg H; Scheiber-Mojdehkar B
Biometals; 2015 Feb; 28(1):35-50. PubMed ID: 25326244
[TBL] [Abstract][Full Text] [Related]
9. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
[TBL] [Abstract][Full Text] [Related]
10. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
Balakrishnan VS; Rao M; Kausz AT; Brenner L; Pereira BJ; Frigo TB; Lewis JM
Eur J Clin Invest; 2009 Jun; 39(6):489-96. PubMed ID: 19397688
[TBL] [Abstract][Full Text] [Related]
12. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
Fell LH; Seiler-Mußler S; Sellier AB; Rotter B; Winter P; Sester M; Fliser D; Heine GH; Zawada AM
Nephrol Dial Transplant; 2016 Nov; 31(11):1835-1845. PubMed ID: 27190361
[TBL] [Abstract][Full Text] [Related]
13. [Importance of the different i.v. iron generations for everyday medical practice].
Biggar P; Hahn KM
MMW Fortschr Med; 2013 Mar; 155 Suppl 1():18-24. PubMed ID: 23678667
[TBL] [Abstract][Full Text] [Related]
14. Ferrous iron content of intravenous iron formulations.
Gupta A; Pratt RD; Crumbliss AL
Biometals; 2016 Jun; 29(3):411-5. PubMed ID: 26956439
[TBL] [Abstract][Full Text] [Related]
15. The cellular transformation of injected colloidal iron complexes into ferritin and hemosiderin in experimental animals; a study with the aid of electron microscopy.
RICHTER GW
J Exp Med; 1959 Feb; 109(2):197-216. PubMed ID: 13620849
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
17. Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a meta-analysis of randomized controlled trials.
Shi L; Zhao Y; Rao A
Afr Health Sci; 2023 Sep; 23(3):205-212. PubMed ID: 38357109
[TBL] [Abstract][Full Text] [Related]
18. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.
Zager RA
Kidney Int; 2005 Oct; 68(4):1533-42. PubMed ID: 16164630
[TBL] [Abstract][Full Text] [Related]
19. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
20. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury.
Zager RA; Johnson AC; Hanson SY; Wasse H
Am J Kidney Dis; 2002 Jul; 40(1):90-103. PubMed ID: 12087566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]